2020 Globoid Cell Leukodystrophy (Krabbe Disease) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Globoid Cell Leukodystrophy (Krabbe Disease) pipeline report presents a comprehensive overview of the research and development of Globoid Cell Leukodystrophy (Krabbe Disease) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Research phase, six drugs in Pre-clinical phase and one drug in Phase 2
As of February 2020, the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Globoid Cell Leukodystrophy (Krabbe Disease) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cell replacements; histone deacetylase inhibitor; PDE inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Globoid Cell Leukodystrophy (Krabbe Disease) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Globoid Cell Leukodystrophy (Krabbe Disease) pipeline drugs profiled in the report include- MSC2, ibudilast, MGTA-456, RND001, BXCL 904, PLX200, GTP-206, PLX300, GALC for Krabbe Disease
As of February 2020, the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline remains robust with 9 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Globoid Cell Leukodystrophy (Krabbe Disease) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cell replacements; histone deacetylase inhibitor; PDE inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Globoid Cell Leukodystrophy (Krabbe Disease) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Globoid Cell Leukodystrophy (Krabbe Disease) development
- Globoid Cell Leukodystrophy (Krabbe Disease) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Globoid Cell Leukodystrophy (Krabbe Disease) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Globoid Cell Leukodystrophy (Krabbe Disease) pipeline candidates included
- Business overview and snapshot of all companies involved in Globoid Cell Leukodystrophy (Krabbe Disease) pipeline are included
- Latest market and pipeline developments are provided in the report
Globoid Cell Leukodystrophy (Krabbe Disease) pipeline drugs profiled in the report include- MSC2, ibudilast, MGTA-456, RND001, BXCL 904, PLX200, GTP-206, PLX300, GALC for Krabbe Disease
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Globoid Cell Leukodystrophy (Krabbe Disease) Condition
2.3 Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Snapshot, 2020
2.4 Companies investing in Globoid Cell Leukodystrophy (Krabbe Disease) pipeline therapeutics
2.5 Phase wise Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Products
2.7 Route of Administration of Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 BioXcel Corporation Overview, Contacts and ASD Pipeline Drugs
3.2 Commence Bio Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Kyorin Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 Magenta Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Passage Bio Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Polaryx Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Polaryx Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Ranedis Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.9 Vascumab LLC Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 MSC2 Drug Details
4.1.1 MSC2 Current Status
4.1.2 MSC2 Drug Overview
4.1.3 MSC2 Mechanism of Action
4.1.4 MSC2 Licensing/Collaboration Companies
4.1.5 MSC2 Clinical Trials
4.2 ibudilast Drug Details
4.2.1 ibudilast Current Status
4.2.2 ibudilast Drug Overview
4.2.3 ibudilast Mechanism of Action
4.2.4 ibudilast Licensing/Collaboration Companies
4.2.5 ibudilast Clinical Trials
4.3 MGTA-456 Drug Details
4.3.1 MGTA-456 Current Status
4.3.2 MGTA-456 Drug Overview
4.3.3 MGTA-456 Mechanism of Action
4.3.4 MGTA-456 Licensing/Collaboration Companies
4.3.5 MGTA-456 Clinical Trials
4.4 RND001 Drug Details
4.4.1 RND001 Current Status
4.4.2 RND001 Drug Overview
4.4.3 RND001 Mechanism of Action
4.4.4 RND001 Licensing/Collaboration Companies
4.4.5 RND001 Clinical Trials
4.5 BXCL 904 Drug Details
4.5.1 BXCL 904 Current Status
4.5.2 BXCL 904 Drug Overview
4.5.3 BXCL 904 Mechanism of Action
4.5.4 BXCL 904 Licensing/Collaboration Companies
4.5.5 BXCL 904 Clinical Trials
4.6 PLX200 Drug Details
4.6.1 PLX200 Current Status
4.6.2 PLX200 Drug Overview
4.6.3 PLX200 Mechanism of Action
4.6.4 PLX200 Licensing/Collaboration Companies
4.6.5 PLX200 Clinical Trials
4.7 GTP-206 Drug Details
4.7.1 GTP-206 Current Status
4.7.2 GTP-206 Drug Overview
4.7.3 GTP-206 Mechanism of Action
4.7.4 GTP-206 Licensing/Collaboration Companies
4.7.5 GTP-206 Clinical Trials
4.8 PLX300 Drug Details
4.8.1 PLX300 Current Status
4.8.2 PLX300 Drug Overview
4.8.3 PLX300 Mechanism of Action
4.8.4 PLX300 Licensing/Collaboration Companies
4.8.5 PLX300 Clinical Trials
4.9 GALC for Krabbe Disease Drug Details
4.9.1 GALC for Krabbe Disease Current Status
4.9.2 GALC for Krabbe Disease Drug Overview
4.9.3 GALC for Krabbe Disease Mechanism of Action
4.9.4 GALC for Krabbe Disease Licensing/Collaboration Companies
4.9.5 GALC for Krabbe Disease Clinical Trials
5. LATEST GLOBOID CELL LEUKODYSTROPHY (KRABBE DISEASE) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Globoid Cell Leukodystrophy (Krabbe Disease) Condition
2.3 Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Snapshot, 2020
2.4 Companies investing in Globoid Cell Leukodystrophy (Krabbe Disease) pipeline therapeutics
2.5 Phase wise Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Products
2.7 Route of Administration of Globoid Cell Leukodystrophy (Krabbe Disease) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 BioXcel Corporation Overview, Contacts and ASD Pipeline Drugs
3.2 Commence Bio Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Kyorin Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 Magenta Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Passage Bio Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Polaryx Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Polaryx Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Ranedis Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.9 Vascumab LLC Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 MSC2 Drug Details
4.1.1 MSC2 Current Status
4.1.2 MSC2 Drug Overview
4.1.3 MSC2 Mechanism of Action
4.1.4 MSC2 Licensing/Collaboration Companies
4.1.5 MSC2 Clinical Trials
4.2 ibudilast Drug Details
4.2.1 ibudilast Current Status
4.2.2 ibudilast Drug Overview
4.2.3 ibudilast Mechanism of Action
4.2.4 ibudilast Licensing/Collaboration Companies
4.2.5 ibudilast Clinical Trials
4.3 MGTA-456 Drug Details
4.3.1 MGTA-456 Current Status
4.3.2 MGTA-456 Drug Overview
4.3.3 MGTA-456 Mechanism of Action
4.3.4 MGTA-456 Licensing/Collaboration Companies
4.3.5 MGTA-456 Clinical Trials
4.4 RND001 Drug Details
4.4.1 RND001 Current Status
4.4.2 RND001 Drug Overview
4.4.3 RND001 Mechanism of Action
4.4.4 RND001 Licensing/Collaboration Companies
4.4.5 RND001 Clinical Trials
4.5 BXCL 904 Drug Details
4.5.1 BXCL 904 Current Status
4.5.2 BXCL 904 Drug Overview
4.5.3 BXCL 904 Mechanism of Action
4.5.4 BXCL 904 Licensing/Collaboration Companies
4.5.5 BXCL 904 Clinical Trials
4.6 PLX200 Drug Details
4.6.1 PLX200 Current Status
4.6.2 PLX200 Drug Overview
4.6.3 PLX200 Mechanism of Action
4.6.4 PLX200 Licensing/Collaboration Companies
4.6.5 PLX200 Clinical Trials
4.7 GTP-206 Drug Details
4.7.1 GTP-206 Current Status
4.7.2 GTP-206 Drug Overview
4.7.3 GTP-206 Mechanism of Action
4.7.4 GTP-206 Licensing/Collaboration Companies
4.7.5 GTP-206 Clinical Trials
4.8 PLX300 Drug Details
4.8.1 PLX300 Current Status
4.8.2 PLX300 Drug Overview
4.8.3 PLX300 Mechanism of Action
4.8.4 PLX300 Licensing/Collaboration Companies
4.8.5 PLX300 Clinical Trials
4.9 GALC for Krabbe Disease Drug Details
4.9.1 GALC for Krabbe Disease Current Status
4.9.2 GALC for Krabbe Disease Drug Overview
4.9.3 GALC for Krabbe Disease Mechanism of Action
4.9.4 GALC for Krabbe Disease Licensing/Collaboration Companies
4.9.5 GALC for Krabbe Disease Clinical Trials
5. LATEST GLOBOID CELL LEUKODYSTROPHY (KRABBE DISEASE) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
